To investigate whether obesity affects the efficacy and safety of tildrakizumab treatment for moderate-to-severe plaque psoriasis of the scalp, specifically hypothesizing that obesity may reduce treatment efficacy.
Key Findings:
Tildrakizumab showed significant improvement in scalp psoriasis regardless of obesity status, with a p-value of <0.05.
Patients treated with tildrakizumab were more likely to achieve prespecified outcomes compared to placebo, with an odds ratio of 2.5.
No new safety signals were identified in patients with obesity, indicating a favorable safety profile.
Interpretation:
The efficacy of tildrakizumab for treating scalp psoriasis is consistent across patients with and without obesity, suggesting it is a viable treatment option regardless of obesity status.
Limitations:
The analysis was exploratory and not powered to detect differences between obesity subgroups, which may limit the generalizability of the findings.
Potential confounding factors related to obesity and psoriasis severity were not fully addressed, which could impact the interpretation of results.
Conclusion:
Tildrakizumab is effective and safe for managing moderate-to-severe scalp psoriasis in obese patients over a 52-week period, suggesting it is a viable treatment option regardless of obesity status.
